This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Case Reports

. 2009 Apr;33(4):565-6.

doi: 10.1016/j.leukres.2008.05.006. Epub 2008 Jun 20.

Gemtuzumab Ozogamicin is a promising post-remission therapy for acute myeloid leukemia

Abdul Rahman El Kinge, Hassan A Hatoum, Rami A Mahfouz, Zaher K Otrock, Elias Jabbour, Hagop Kantarjian, Ali Bazarbachi

PMID: 18571231
DOI: 10.1016/j.leukres.2008.05.006

Case Reports

Gemtuzumab Ozogamicin is a promising post-remission therapy for acute myeloid leukemia

Abdul Rahman El Kinge et al. Leuk Res. 2009 Apr.

. 2009 Apr;33(4):565-6.

doi: 10.1016/j.leukres.2008.05.006. Epub 2008 Jun 20.

Authors

Abdul Rahman El Kinge, Hassan A Hatoum, Rami A Mahfouz, Zaher K Otrock, Elias Jabbour, Hagop Kantarjian, Ali Bazarbachi

PMID: 18571231
DOI: 10.1016/j.leukres.2008.05.006

No abstract available

PubMed Disclaimer

Similar articles

Postremission gemtuzumab ozogamicin for elderly patients with acute myelogenous leukemia with favorable characteristics and comorbid conditions.
Ichikawa M, Hangaishi A, Nannya Y, Kurokawa M. Ichikawa M, et al. Int J Hematol. 2010 Nov;92(4):673-4. doi: 10.1007/s12185-010-0711-9. Epub 2010 Oct 28. Int J Hematol. 2010. PMID: 20978876 No abstract available.
Gemtuzumab ozogamicin: is there room for salvage?
Clarke WT, Marks PW. Clarke WT, et al. Blood. 2010 Oct 7;116(14):2618-9. doi: 10.1182/blood-2010-08-300871. Blood. 2010. PMID: 20930085 No abstract available.
Influence of NPM1 and FLT3-ITD status on outcome in relapsed/refractory AML patients receiving salvage therapy including gemtuzumab ozogamicin.
Chevallier P, Prebet T, Pigneux A, Hunault M, Delaunay J, Perry F, Lode L, Richebourg S, Blanchet O, Vey N, Ifrah N, Milpied N, Blaise D, Harousseau JL, Mohty M. Chevallier P, et al. Leukemia. 2010 Feb;24(2):467-9. doi: 10.1038/leu.2009.214. Epub 2009 Oct 22. Leukemia. 2010. PMID: 19847200 No abstract available.
[Gemtuzumab ozogamicin for treatment of acute myeloid leukemia].
Brotelle T, Lemal R, Moluçon-Chabrot C, Bay JO, Delaunay J, Guièze R. Brotelle T, et al. Bull Cancer. 2014 Feb;101(2):211-8. doi: 10.1684/bdc.2014.1886. Bull Cancer. 2014. PMID: 24557850 Review. French.
Gemtuzumab ozogamicin: an anti-CD33 immunoconjugate for the treatment of acute myeloid leukaemia.
Stasi R. Stasi R. Expert Opin Biol Ther. 2008 Apr;8(4):527-40. doi: 10.1517/14712598.8.4.527. Expert Opin Biol Ther. 2008. PMID: 18352855 Review.

See all similar articles

Cited by

Postremission gemtuzumab ozogamicin for elderly patients with acute myelogenous leukemia with favorable characteristics and comorbid conditions.
Ichikawa M, Hangaishi A, Nannya Y, Kurokawa M. Ichikawa M, et al. Int J Hematol. 2010 Nov;92(4):673-4. doi: 10.1007/s12185-010-0711-9. Epub 2010 Oct 28. Int J Hematol. 2010. PMID: 20978876 No abstract available.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information